Clinical trial NCT02053974: Spironolactone Against Anthracycline-induced Cardiomyopathy
Official title: Protective Effects of Spironolactone Against Anthracycline Induced Cardiomyopathy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Anthracycline Induced Cardiotoxicity
Keywords: Anthracycline
spironolactone
cardiotoxicity
Lead sponsor: TC Erciyes University
Sponsor class: OTHER
First posted: 2014-02-04
Enrollment: 90
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study sought to investigate the whether spironolactone protects the heart against anthracycline-induced cardiotoxicity.

Detailed description: Anthracyclines are the cornerstone in the treatment of numerous hematological and solid cancers. The most common side effect of anthracycline is cardiotoxicity and this may limits its use and increases the rate of mortality and morbidity. Cardiotoxicity is cumulative, dose dependent, and irreversible. Improvements in protective mechanisms against the cardiotoxicity of anthracycline are important to prevent the discontinuance of these chemotherapeutics.

Spironolactone is an aldosterone antagonist which blocks the last step of the rennin angiotensin aldosterone system (RAAS). The RAAS is one of the most effective systems in remodeling of the myocardium in post-myocardial damage. According to the RALES study, in patients with severe heart failure, 25 mg spironolactone per day in addition to the standard therapy has positive effects, particularly on cardiac fibrosis and on remodeling, and substantially reduces the risk of both morbidity and death. In the EPHESUS study, it has been shown that, after the myocardial damage due to infarction, the administration of aldosterone antagonists had positive effects on the remodeling process, left ventricular ejection fraction and primer end-points. In the present study, we tested the hypothesis that RAAS blockage with spironolactone may reduce the cardiotoxicity of anthracycline group chemotherapeutics.

Eligibility criteria: Inclusion Criteria:

* LVEF \>50%
* first diagnosed breast cancer
* female sex

Exclusion Criteria:

* Prior breast cancer and/or prior anthracycline exposure history
* LVEF \<50%
* Use of angiotensin converting enzyme inhibitors, angiotensin receptor blockers and beta blockers
* Creatinin value \>2 mg/dl
* Presence of chronic kidney failure
* Potassium value \>5.3 mg/dl
* Presence of adrenal gland diseases,
* Presence of severe liver failure
* Co-morbidities such as coronary heart disease, hypertension, atrial fibrillation, and valvular heart disease.
* Male patients were excluded for the homogenization of the study

Primary outcomes:
measure: Decrease in left ventricular ejection fraction
timeFrame: 24 weeks on average
Secondary outcomes:
Other outcomes:
Locations:
city: Kayseri
country: Turkey
facility: Erciyes University School of Medicine
Study officials:
affiliation: Erciyes University School of Medicine
name: Mahmut Akpek, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, Berk V, Karaca H, Kalay N, Oguzhan A, Ergin A. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 2015 Jan;17(1):81-9. doi: 10.1002/ejhf.196. Epub 2014 Nov 20.